NASDAQ:AUPH

Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

$5.09
+0.04 (+0.79%)
(As of 04/23/2024 ET)
Today's Range
$5.02
$5.16
50-Day Range
$4.81
$7.97
52-Week Range
$4.71
$12.43
Volume
920,650 shs
Average Volume
2.18 million shs
Market Capitalization
$736.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Aurinia Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
96.5% Upside
$10.00 Price Target
Short Interest
Bearish
9.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.28mentions of Aurinia Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.06) to $0.55 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.68 out of 5 stars

Medical Sector

839th out of 909 stocks

Pharmaceutical Preparations Industry

395th out of 425 stocks

AUPH stock logo

About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

AUPH Stock Price History

AUPH Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
11 Oversold Biotech Stocks To Buy Right Now
AUPH Mar 2024 3.000 call
Aurinia Pharmaceuticals Inc (AUPH)
AUPH Oct 2024 8.000 call
AUPH Jan 2025 15.000 call
AUPH Oct 2024 6.000 put
See More Headlines
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
4/23/2024
Next Earnings (Confirmed)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AUPH
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$13.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+95.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-78,020,000.00
Pretax Margin
-44.14%

Debt

Sales & Book Value

Annual Sales
$175.51 million
Book Value
$2.63 per share

Miscellaneous

Free Float
138,399,000
Market Cap
$739.01 million
Optionable
Optionable
Beta
1.36
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives


AUPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Aurinia Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AUPH shares.
View AUPH analyst ratings
or view top-rated stocks.

What is Aurinia Pharmaceuticals' stock price target for 2024?

4 analysts have issued twelve-month price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price targets range from $8.00 to $13.00. On average, they anticipate the company's share price to reach $10.00 in the next year. This suggests a possible upside of 96.5% from the stock's current price.
View analysts price targets for AUPH
or view top-rated stocks among Wall Street analysts.

How have AUPH shares performed in 2024?

Aurinia Pharmaceuticals' stock was trading at $8.99 at the beginning of the year. Since then, AUPH stock has decreased by 43.4% and is now trading at $5.09.
View the best growth stocks for 2024 here
.

Are investors shorting Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 12,240,000 shares, an increase of 14.9% from the March 15th total of 10,650,000 shares. Based on an average trading volume of 2,340,000 shares, the short-interest ratio is presently 5.2 days. Approximately 9.6% of the shares of the stock are short sold.
View Aurinia Pharmaceuticals' Short Interest
.

When is Aurinia Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AUPH earnings forecast
.

How can I listen to Aurinia Pharmaceuticals' earnings call?

Aurinia Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) issued its earnings results on Thursday, February, 15th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.03. The biotechnology company earned $45.10 million during the quarter, compared to analysts' expectations of $45 million. Aurinia Pharmaceuticals had a negative net margin of 44.45% and a negative trailing twelve-month return on equity of 20.10%. The business's revenue for the quarter was up 58.8% on a year-over-year basis. During the same period last year, the company earned ($0.18) earnings per share.

What ETF holds Aurinia Pharmaceuticals' stock?

Virtus LifeSci Biotech Products ETF holds 42,195 shares of AUPH stock, representing 1.16% of its portfolio.

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sunbelt Securities Inc. (0.13%), Hennion & Walsh Asset Management Inc. (0.05%) and PFG Investments LLC (0.01%). Insiders that own company stock include David RW Jayne, George M Milne Jr, Jill Leversage, Joseph M Miller, Joseph P Hagan, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends
.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AUPH) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners